linjc16/ctgov huggingface dataset:
Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

Study Overview
=================
Brief Summary
-----------------
Postpartum depression (PPD) represent around 15% of birth in developed countries. The context of the COVID-19 epidemy represents a possible source of additional emotional distress. The objective of this study is to determine the screening prevalence and risk factors of postpartum depression, among women who deliver in fourth hospital in the North of France in the context of the COVID epidemy.

Official Title
-----------------
Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

Conditions
-----------------
Postpartum Depression, Covid19, Prevalence, Social Distance

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Single baby delivery alive new born child without admission in neonatal intensive care unit French-speaking mother mother older than 18 years old Exclusion Criteria: Patients who refuses the inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Questionnaire|The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation of prevalence of clinically-significant post-partum depressive symptoms | Variation of prevalence of clinically-significant post-partum depressive symptoms | up to 35 days after delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postpartum Depression, Covid19, Prevalence, Social Distance
Evaluation of Cognitive Function in a Suicidal Crisis

Study Overview
=================
Brief Summary
-----------------
The aftermath of suicide is devastating, being the cause of 800 000 deaths every year worldwide. In France, suicide still causes about 10 000 deaths per year and the number of suicide attempts (SA) is estimated between 170 000 and 200 000 per year (InVS). It is often thought that a suicidal crisis is only related to depression, as it actually is a far more complex phenomenon. A suicidal crisis can occur on various grounds like psychiatric disorders but also contextual events or somatic diseases and it has been hypothesized that suicidal ideas or inclinations could have a common and independent cognitive origin

Official Title
-----------------
Evaluation of Cognitive Function in a Suicidal Crisis and Interest to Achieve a MoCA Test in Acute Situations

Conditions
-----------------
Suicide

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal or corrected vision Having understood the information not and having signed the form of consent Being hospitalized for suicidal ideas (Score with inclusion at the level of Beck > 3) or after a suicide attempt of less than one week. Exclusion criteria: Pregnant woman and/or nursing Diagnosed irrational pathology Known proven intellectual deficiency Patient whose physical or mental status does not allow to pass the tests of the study Being under supervision or trusteeship or private of freedom or in emergency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients having a score in MoCA test strictly under 26 |  | at inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation in MoCA test scores between before (V1) and after hospitalization (V2) |  | an average at 3 months after inclusion | 
| Variation in scores to the subtests between between before (V1) and after hospitalization (V2) |  | an average at 3 months after inclusion | 
| Rate of patients having lower subtests scores than the standards |  | an average at 3 months after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cognitive functions, MoCA test
Daily Ultrasound-screening for CVC-related Thrombosis

Study Overview
=================
Brief Summary
-----------------
The central venous catheters (CVC) related thrombosis is an issue of importance to ICU clinicians.This study conducts the daily ultrasound-screening for CVC-related thrombosis (DUCT).Its aim is to evaluate the characteristic and regularity of the central venous catheters (CVC) related thrombosis in ICU patients, and optimize the screening program of CVC-related thrombosis.

Official Title
-----------------
Daily Ultrasound-screening for CVC-related Thrombosis in Intensive Care Patients

Conditions
-----------------
Central Venous Catheter Thrombosis, Critical Illness, Ultrasonography

Intervention / Treatment
-----------------
* Device: ultrasound-screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients at least 18 years of age, expected to need a central venous catheterization for at least 48h in ICU. Exclusion Criteria: Patients with infection or inflammation or local trauma at the insertion site.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Characteristic and regularity of CRT<br>The patients who have a central venous catheterization conduct the daily ultrasound-screening for CVC-related Thrombosis (DUCT). | Device: ultrasound-screening<br>* Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the incidence rate of central venous catheters related thrombosis (CRT) | the percentage of patients who have CRT in all patients included. | the assessment time will be from the time patients admitted in ICU to the time leaving ICU, less than 6 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the time when the central venous catheters related thrombosis (CRT) occured | which day the CRT is found after central venous catheter. | the assessment time will be from the time patients admitted in ICU to the time leaving ICU, less than 6 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
central venous catheters, venous thrombosis, ultrasound, critical care
Pain Relief Investigation of NeuroModulation Therapy in Adult Humans

Study Overview
=================
Brief Summary
-----------------
The study is being performed to determine the efficacy and safety of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain.

Official Title
-----------------
PRIMA Study: Pain Relief Investigation of NeuroModulation Therapy in an Adult Population: A Double Blind, Randomized, Multicenter, Placebo Controlled Trial.

Conditions
-----------------
Chronic Musculoskeletal Pain

Intervention / Treatment
-----------------
* Device: PRIMA


Participation Criteria
=================

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: PRIMA|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluation of Knowledge- Attitude- Practice (KAP) of Intern Dentists in Emergency Management of Traumatic Dental Injuries in Permanent Anterior Teeth

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate knowledge, Attitude and Practice of intern dentists in emergency management of traumatic dental injuries in permanent anterior teeth in children aged from 6 to 12 years old. A questionnaire survey will be designed to evaluate Knowledge - Attitude - and practice (KAP) of intern dentists who met the eligibility criteria.

Official Title
-----------------
Evaluation of Knowledge- Attitude- Practice (KAP) of Intern Dentists in Emergency Management of Traumatic Dental Injuries in Permanent Anterior Teeth: A Cross-sectional Study

Conditions
-----------------
Traumatized Permanent Anterior Teeth

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intern dentists attending their internship in Faculty of Dentistry- Cairo University, other private university (Modern Science and Arts University- MSA). The intern dentists who agree to participate. Intern dentists who did not attend Pediatric Dentistry round, Endodontic round, Emergency round and Surgery round at Cairo University. Intern dentists irrespective of age and sex.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge, attitude and practice (KAP) of intern dentists. | Measured by a KAP questionnaire and the measuring Unit is Binary ( Yes, No) | 1 year | 
| Knowledge, attitude and practice (KAP) of intern dentists. | Measured by a KAP questionnaire and the measuring Unit is Multiple choice questions. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dental trauma, Emergency management, Tooth avulsion, Knowledge, Practice, Traumatic injuries, Attitude
ACT-128800 in Psoriasis

Study Overview
=================
Brief Summary
-----------------
This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.

Official Title
-----------------
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis

Conditions
-----------------
Plaque Psoriasis

Intervention / Treatment
-----------------
* Drug: ACT-128800
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult males and females with moderate to severe plaque psoriasis who require systemic treatment and for whom participation in a placebo-controlled study of an investigational drug is justified. Exclusion Criteria: Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis. Systemic or topical treatments for psoriasis other than emollients. Ongoing bacterial, viral or fungal infections. History or presence of malignancy. Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: ACT-128800<br>* ACT-128800 administered orally once daily<br>|
| Placebo Comparator: B<br> | Drug: Placebo<br>* Matching placebo capsules administered orally once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit. |  | Baseline to week 6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clear - almost clear Physician Global Assessment (PGA) at Week 6 visit. |  | Week 6 |
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and metformin as monotherapy

Official Title
-----------------
MK-0431/ONO-5435 Phase III Clinical Study - Metformin Add-On Study for Patients With Type 2 Diabetes Mellitus

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: Sitagliptin phosphate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with type 2 diabetes mellitus on diet/exercise therapy and metformin as monotherapy Exclusion Criteria: Patients with type 1 diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: P<br> | Drug: Placebo<br>* Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD<br>|
| Experimental: E<br> | Drug: Sitagliptin phosphate<br>* Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | 12 weeks | 
| safety |  | 52 weeks | 
| tolerability |  | 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma glucose |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ONO-5435, MK-0431, Type 2 diabetes mellitus
Effects of Topical Insulin on Levels of Tear Inflammatory Mediators

Study Overview
=================
Brief Summary
-----------------
60 samples are take to determine the effects of topical insulin on tear inflammatory mediators interleukin 1a, interleukin 6 and matrix metalloprotenase 9 in diabetics with dry eye disease.

Detailed Description
-----------------
Tear samples are taken to compare the levels of inflammatory markers (IL 1a, IL6 and MMP 9) pre-and post treatment with topical insulin in normal saline compared to standard therapy and normal saline in diabetics with dry eyes and also to correlate the IL 1a, IL6 and MMP 9 levels with clinical outcomes in diabetics with dry eyes treated with topical insulin in normal saline, standard therapy and normal saline

Official Title
-----------------
Effects of Topical Insulin on Levels of Tear Inflammatory Mediators Compared to Standard Artificial Tears and Normal Saline in Diabetics With Dry Eye Disease

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Drug: Topical Insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all diabetics aged 18 - 50 years of age with at least mild OSDI scores Exclusion Criteria: Diabetics on contact lenses Diabetic with history of ocular surgery in the preceding 3 months Post menopausal women Known mild dry eye with prior usage of topical therapy who are unable to discontinue Known case of allergic eye disease Sjogren's syndrome patients Unwilling or unable to attend 6 follow up and sampling sessions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Topical Insulin<br>Insulin (Actrapid) diluted in normal saline | Drug: Topical Insulin<br>* Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks<br>* Other names: Gutt insulin;|
| Placebo Comparator: Normal Saline<br>Normal saline eyedrops | Drug: Topical Insulin<br>* Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks<br>* Other names: Gutt insulin;|
| Active Comparator: Standard Artifical Tear<br>Gutt systane ultra | Drug: Topical Insulin<br>* Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks<br>* Other names: Gutt insulin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical marker 1 | Interleuikn 1-alpha | 4 weeks | 
| Biochemical marker 2 | Interleukin 6 | 4 weeks | 
| Biochemical marker 3 | Matrix metallo-proteinase 9 | 4 weeks |
Light Based Analysis of Developing Breast Tissue in Adolescent Girls: a Feasibility Study

Study Overview
=================
Brief Summary
-----------------
The proposed pilot study attempts to investigate the feasibility of Optical Spectroscopy (OS) as a method to quantify breast tissue composition and density in adolescent females. Our goals include: to assess whether adolescent girls can be instructed to assist with the OS measurement procedure and to determine the OS technique's ability to show breast tissue composition and density in adolescent breast tissue.

Detailed Description
-----------------
The period between menarche and the age of first full-term pregnancy has been identified as being most crucial for establishing an individual's future breast cancer risk. Epidemiological studies further suggest exposures, such as foods and toxins, during adolescence to have a significant impact on the likelihood of transformation in the developing breast resulting in cancer later in life. Adolescent diet affects mammary development directly and indirectly by influencing the micronutrients and the hormonal status of the adolescent. The goal of this study is to investigate the feasibility of Optical Spectroscopy (OS), a method based on differential light scattering and absorption in tissue, to quantify bulk breast tissue properties in adolescent females.

Official Title
-----------------
Pilot Study to Investigate the Feasibility of Optical Spectroscopy to Quantify Bulk Breast Tissue Properties in Girls Age 10 - 14 Years

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (Girls): Are in good health and are able to provide assent Are between the ages of 10 and 14 Are interested in participating in this study Are willing to come, accompanied by a parent, to the Princess Margaret Hospital Inclusion Criteria (Parents): Are able to provide consent Are willing to accompany your daughter to the Princess Margaret Hospital for one visit of about 45 minutes Exclusion Criteria (Girls): Have had previous surgeries to the chest area

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optical Transillumination Spectroscopy, Breast Cancer Risk
Effects of Remifentanil Infusion on Emergence Delirium After Dental Surgery in Children

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators tried to show the effect of remifentanil on emergence delirium caused by sevoflurane used in general anesthesia.We planned a retrospective study. We formed two groups of 80 participants. One group included patients who were received remifentanil infusion during general anesthesia.The other group included patients who were received only sevoflurane inhalation anesthesia. The patients included in the study were evaluated for emergence delirium in the postoperative period be evaluating the past recorded informations.

Official Title
-----------------
Effects of Remifentanil Infusion on Emergence Delirium After Dental Surgery in Children

Conditions
-----------------
Emergence Delirium

Intervention / Treatment
-----------------
* Other: The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria American Society of Anesthesiologists score 1-2 - Exclusion Criteria: neurological disease, psychiatric illness

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sevoflurane only<br>inhalation of sevoflurane during general anesthesia | Other: The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively<br>* routine remifentanil infusion during general anesthesia<br>|
| Remifentanil and Sevoflurane<br>remifentanil infusion and inhalation of sevoflurane during general anesthesia | Other: The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively<br>* routine remifentanil infusion during general anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| emergence delirium | incidence of emergence delirium | 30 minute after operation |